Clinical trials: Mild Dementia
Alzheimer's Disease
OmegAD (Omega-3 and Alzheimer's Disease)
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA.
- Trial name
- NCT00211159
- Testing
- EPAX 1050TG
- Where
- Sweden
- Volunteers
- 204 people
- Sponsor
- Karolinska University Hospital
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Mild Cognitive Impairment
An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine
The purpose of the study is to collect data of patients who were randomized (assignment of study medication by chance) and treated in 3 previous studies of galantamine (CR003145, CR002014 and CR005947) for the treatment of mild…
- Trial name
- NCT00297414
- Testing
- No intervention
- Where
- 144 sites in United States, Argentina and 14 more
- Volunteers
- 1,083 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Parkinson Disease, Mild Cognitive Impairment
Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease
The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD).
- Conditions
- Parkinson Disease, Mild Cognitive Impairment, Memory Impairment
- Trial name
- TRIP (NCT04643327)
- Testing
- Levetiracetam
- Where
- Australia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet